Q1 2025 Earnings Call Transcript September 16, 2024 ImmunoPrecise Antibodies Ltd. misses on earnings expectations. Reported ...
ImmunoPrecise Antibodies Ltd. (IPA) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.11 per share a year ago. These ...
3d
ImmunoPrecise Antibodies (IPA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst ...
IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ: IPA), an artificial intelligence-driven biotherapeutic ...
ImmunoPrecise Antibodies will report earnings from Q1.Analysts on Wall Street expect ImmunoPrecise Antibodies will release ...
ImmunoPrecise Antibodies Ltd. is a therapeutic antibody discovery company, which engages in the provision of human therapeutic antibody discovery and development services. The firm offers a ...
Good morning, ladies and gentlemen, and thank you for joining us today for ImmunoPrecise Antibodies First Quarter Fiscal Year 2025 Earnings Call. We appreciate your time and interest in our company.
IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA), an artificial intelligence-driven biotherapeutic research and technology company, today reported financial results for ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
3d
Despite a year-over-year revenue decline, IPA shows promising growth in key labs and strategic advancements in AI-driven ...
VICTORIA, British Columbia--(BUSINESS WIRE)-- IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA), an artificial intelligence-driven ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback